- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07629479
Ejaculation-Preserving Versus Standard Bipolar TUEP for BPH (EP-BTUEP)
Bipolar Transurethral Enucleation of the Prostate With Preservation of Ejaculation in Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Trial
Studienübersicht
Status
Detaillierte Beschreibung
Benign prostatic hyperplasia is a common cause of lower urinary tract symptoms in aging men. Surgical treatment is indicated when medical therapy fails or when symptoms remain bothersome. Bipolar transurethral enucleation of the prostate is an established endoscopic surgical technique for benign prostatic obstruction, but standard endoscopic prostate surgery may be associated with loss of antegrade ejaculation.
This study will evaluate whether an ejaculation-preserving modification of bipolar transurethral enucleation of the prostate can preserve ejaculatory function while maintaining effective relief of lower urinary tract symptoms. The ejaculation-preserving technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum. The control group will undergo standard bipolar transurethral enucleation of the prostate.
Eligible sexually active men with benign prostatic hyperplasia and lower urinary tract symptoms after failed medical treatment will be randomized in a 1:1 ratio to ejaculation-preserving B-TUEP or standard B-TUEP. Sexual and urinary outcomes will be assessed using validated questionnaires and objective urinary parameters. Follow-up assessments will include ejaculatory function, erectile function, International Prostate Symptom Score, post-void residual urine, uroflowmetry, perioperative complications, and need for retreatment.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Hany F Badawy, MD
- Telefonnummer: +201149525028
- E-Mail: HANYFATHY86@GMAIL.COM
Studienorte
-
-
Beni Suweif Governorate
-
Banī Suwayf, Beni Suweif Governorate, Ägypten
- Rekrutierung
- Department of Urology- Beni-Suef University Hospitals
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Male patients with lower urinary tract symptoms secondary to benign prostatic obstruction after failed medical treatment for at least 3 months.
- Sexually active patients with a continuous relationship with the same partner.
- International Prostate Symptom Score of 8 or greater.
- Transrectal ultrasound-estimated prostate size between 40 and 100 cc.
- Eligible for bipolar transurethral enucleation of the prostate.
- Ability to complete the required sexual and urinary function questionnaires.
- Ability to provide written informed consent.
Exclusion Criteria:
- Preoperative sexual dysfunction.
- Preoperative ejaculatory dysfunction.
- Diagnosis or suspicion of prostate cancer.
- Neurological disorders affecting lower urinary tract or sexual function.
- Detrusor hypocontractility.
- Catheter-dependent patients.
- Patients with bladder stones.
- Inability or refusal to provide informed consent.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Ejaculation-Preserving B-TUEP
Participants assigned to this arm will undergo ejaculation-preserving bipolar transurethral enucleation of the prostate.
The technique will preserve the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
Ejaculation-preserving bipolar transurethral enucleation of the prostate will be performed with preservation of the paracollicular tissue, the area approximately 1 cm proximal to the verumontanum, and bladder neck fibers, while avoiding deep enucleation behind the verumontanum.
|
|
Aktiver Komparator: Standard B-TUEP
Participants assigned to this arm will undergo standard bipolar transurethral enucleation of the prostate without the ejaculation-preserving modifications used in the experimental arm.
|
Standard bipolar transurethral enucleation of the prostate will be performed according to the conventional surgical technique without preservation of the paracollicular tissue and the area approximately 1 cm proximal to the verumontanum.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Function Score From Baseline to 6 Months
Zeitfenster: Baseline and 6 months postoperatively
|
Ejaculatory function will be assessed using the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form function score.
The function score is based on three ejaculatory function items assessing ejaculation frequency, ejaculation force, and ejaculation volume.
The total function score ranges from 1 to 15, with higher scores indicating better ejaculatory function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
A smaller decrease or a positive change indicates better preservation of ejaculatory function.
|
Baseline and 6 months postoperatively
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form Bother Score at 6 Months
Zeitfenster: 6 months postoperatively
|
Ejaculatory bother will be assessed using the bother item of the Male Sexual Health Questionnaire Ejaculatory Dysfunction Short Form.
The bother score ranges from 0 to 5, with higher scores indicating greater bother related to ejaculatory dysfunction.
|
6 months postoperatively
|
|
Preservation of Antegrade Ejaculation at 6 Months
Zeitfenster: 6 months postoperatively
|
The proportion of participants with preserved antegrade ejaculation at 6 months after surgery will be compared between the ejaculation-preserving B-TUEP group and the standard B-TUEP group.
Preserved antegrade ejaculation will be defined as patient-reported antegrade seminal emission during orgasm after resumption of sexual activity.
Participants reporting absent ejaculation, dry ejaculation, or retrograde ejaculation will be considered not to have preserved antegrade ejaculation.
|
6 months postoperatively
|
|
Change in International Index of Erectile Function-5 Score From Baseline to 6 Months
Zeitfenster: Baseline and 6 months postoperatively
|
Erectile function will be assessed using the International Index of Erectile Function-5 questionnaire.
The total score ranges from 5 to 25, with higher scores indicating better erectile function.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in International Prostate Symptom Score From Baseline to 6 Months
Zeitfenster: Baseline and 6 months postoperatively
|
Lower urinary tract symptoms will be assessed using the International Prostate Symptom Score.
The total score ranges from 0 to 35, with higher scores indicating more severe urinary symptoms.
The outcome will be calculated as the 6-month postoperative score minus the baseline score.
|
Baseline and 6 months postoperatively
|
|
Change in Maximum Urinary Flow Rate From Baseline to 6 Months
Zeitfenster: Baseline and 6 months postoperatively
|
Maximum urinary flow rate will be measured by uroflowmetry and reported in milliliters per second.
The outcome will be calculated as the 6-month postoperative maximum urinary flow rate minus the baseline maximum urinary flow rate.
|
Baseline and 6 months postoperatively
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Hany F Badawy, MD, Faculty of medicine Beni-Suef University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- FMBSUREC07092025EjBTUEP
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .